The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
Identifieur interne : 000999 ( Istex/Corpus ); précédent : 000998; suivant : 000A00The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
Auteurs : Rachael S. FelberbaumSource :
- Biotechnology Journal [ 1860-6768 ] ; 2015-05.
Abstract
The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.
The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.
Url:
DOI: 10.1002/biot.201400438
Links to Exploration step
ISTEX:B294EB921F41F8D7654A04E9AC4BE437F004790DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title><author><name sortKey="Felberbaum, Rachael S" sort="Felberbaum, Rachael S" uniqKey="Felberbaum R" first="Rachael S." last="Felberbaum">Rachael S. Felberbaum</name><affiliation><mods:affiliation>Protein Sciences Corporation, Meriden, CT, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: rfelberbaum@proteinsciences.com</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B294EB921F41F8D7654A04E9AC4BE437F004790D</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/biot.201400438</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000999</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000999</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title><author><name sortKey="Felberbaum, Rachael S" sort="Felberbaum, Rachael S" uniqKey="Felberbaum R" first="Rachael S." last="Felberbaum">Rachael S. Felberbaum</name><affiliation><mods:affiliation>Protein Sciences Corporation, Meriden, CT, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: rfelberbaum@proteinsciences.com</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Biotechnology Journal</title><title level="j" type="sub">Vaccine Biotechnology</title><title level="j" type="alt">BIOTECHNOLOGY JOURNAL</title><idno type="ISSN">1860-6768</idno><idno type="eISSN">1860-7314</idno><imprint><biblScope unit="vol">10</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="702">702</biblScope><biblScope unit="page" to="714">714</biblScope><biblScope unit="page-count">13</biblScope><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2015-05">2015-05</date></imprint><idno type="ISSN">1860-6768</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1860-6768</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.</div><div type="abstract" xml:lang="en">The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>recombinant</json:string><json:string>bevs</json:string><json:string>baculovirus</json:string><json:string>insect cell</json:string><json:string>bevs platform</json:string><json:string>influenza</json:string><json:string>biotechnol</json:string><json:string>biotechnology</json:string><json:string>baculoviruses</json:string><json:string>hemagglutinin</json:string><json:string>verlag gmbh</json:string><json:string>gene therapy</json:string><json:string>verlag</json:string><json:string>kgaa</json:string><json:string>gmbh</json:string><json:string>weinheim</json:string><json:string>flublok</json:string><json:string>raav</json:string><json:string>viral</json:string><json:string>glybera</json:string><json:string>coronavirus</json:string><json:string>glycoprotein</json:string><json:string>immunogenicity</json:string><json:string>subunit</json:string><json:string>influenza vaccine</json:string><json:string>chikungunya</json:string><json:string>mammalian cell</json:string><json:string>pathogen</json:string><json:string>immune</json:string><json:string>virol</json:string><json:string>biol</json:string><json:string>plo</json:string><json:string>cervarix</json:string><json:string>raavs</json:string><json:string>biotechnology journal biotechnol</json:string><json:string>cell line</json:string><json:string>recombinant protein</json:string><json:string>influenza virus</json:string><json:string>weinheim biotechnology journal biotechnol</json:string><json:string>baculovirus expression vector system</json:string><json:string>recombinant technology</json:string><json:string>recombinant baculoviruses</json:string><json:string>protein science corporation</json:string><json:string>pandemic influenza vaccine</json:string><json:string>recombinant virus</json:string><json:string>baculovirus vector</json:string><json:string>recombinant baculovirus</json:string><json:string>protein production</json:string><json:string>immune response</json:string><json:string>baculovirus expression system</json:string><json:string>gene</json:string><json:string>pandemic</json:string><json:string>high yield</json:string><json:string>regulatory agency</json:string><json:string>wide variety</json:string><json:string>bevsderived product</json:string><json:string>attractive platform</json:string><json:string>adventitious agent</json:string><json:string>insect cell line</json:string><json:string>transfer plasmid</json:string><json:string>single cell line</json:string><json:string>high level</json:string><json:string>seasonal influenza</json:string><json:string>recombinant hemagglutinin</json:string><json:string>adult year</json:string><json:string>recent product approval</json:string><json:string>viral vaccine</json:string><json:string>lethal challenge</json:string><json:string>vaccine candidate</json:string><json:string>ingelvac circoflex</json:string><json:string>manufacturing platform</json:string><json:string>regulatory approval</json:string><json:string>autographa californica nuclear polyhedrosis virus</json:string><json:string>gene therapy vector</json:string><json:string>virus</json:string><json:string>syndrome</json:string><json:string>traditional vaccine manufacturing</json:string><json:string>disease control</json:string><json:string>large size</json:string><json:string>seed virus</json:string><json:string>seasonal influenza vaccine</json:string><json:string>bevs process</json:string><json:string>product design</json:string><json:string>commercial manufacturing platform</json:string><json:string>viral vaccine production</json:string><json:string>influenza vaccine field</json:string><json:string>important consideration</json:string><json:string>life technology</json:string><json:string>senior director</json:string><json:string>commercial production</json:string><json:string>large scale</json:string><json:string>dangerous pathogen</json:string><json:string>single baculovirus</json:string><json:string>virus bank</json:string><json:string>gene delivery vector</json:string><json:string>gene expression</json:string><json:string>alipogene tiparvovec</json:string><json:string>clinical study</json:string><json:string>clinical development</json:string><json:string>retinal degeneration</json:string><json:string>duchenne muscular dystrophy</json:string><json:string>research tool</json:string><json:string>porcine circovirus type</json:string><json:string>pandemic influenza</json:string><json:string>protein expression</json:string><json:string>cabbage looper</json:string><json:string>bevs platform feature</json:string><json:string>subunit vaccine candidate</json:string><json:string>regulatory perspective</json:string><json:string>last decade</json:string><json:string>vaccine design</json:string><json:string>whole virion</json:string><json:string>gene therapy product candidate</json:string><json:string>phase phase</json:string><json:string>vault particle</json:string><json:string>good example</json:string><json:string>severe acute respiratory syndrome</json:string><json:string>middle east respiratory syndrome</json:string><json:string>vaccine manufacturing</json:string><json:string>subunit vaccine</json:string><json:string>membrane protein</json:string><json:string>veterinary vaccine</json:string><json:string>heavy chain domain</json:string><json:string>business development</json:string><json:string>cell expression system</json:string><json:string>baculovirus expression vector</json:string><json:string>manufacturing purpose</json:string><json:string>protective antigen</json:string><json:string>corporate communication</json:string><json:string>antigenic drift</json:string><json:string>cysteine residue</json:string><json:string>recombinant hemagglutinin protein</json:string><json:string>vaccine antigen</json:string><json:string>coronavirus neutralizing antibody</json:string><json:string>lepidopteran insect cell</json:string><json:string>expert opin</json:string><json:string>recombinant viral vector</json:string><json:string>vector development</json:string><json:string>recombinant influenza hemagglutinin</json:string><json:string>drug target</json:string><json:string>mouse model</json:string><json:string>severe acute respiratory syndrome coronavirus</json:string><json:string>chikungunya particle</json:string><json:string>reingard grabherr</json:string><json:string>effective vaccine</json:string></teeft></keywords><author><json:item><name>Rachael S. Felberbaum</name><affiliations><json:string>Protein Sciences Corporation, Meriden, CT, USA</json:string><json:string>E-mail: rfelberbaum@proteinsciences.com</json:string><json:string>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Adeno‐associated virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Baculovirus insect cell system</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Gene therapy vectors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Influenza vaccine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Viral vaccines</value></json:item></subject><articleId><json:string>BIOT201400438</json:string></articleId><arkIstex>ark:/67375/WNG-C4V1L7GV-1</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.</abstract><qualityIndicators><score>9.46</score><pdfWordCount>9022</pdfWordCount><pdfCharCount>61429</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>15</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><pdfWordsPerPage>601</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>205</abstractWordCount><abstractCharCount>1455</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title><genre><json:string>review-article</json:string></genre><host><title>Biotechnology Journal</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1860-7314</json:string></doi><issn><json:string>1860-6768</json:string></issn><eissn><json:string>1860-7314</json:string></eissn><publisherId><json:string>BIOT</json:string></publisherId><volume>10</volume><issue>5</issue><pages><first>702</first><last>714</last><total>13</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Review</value></json:item><json:item><value>Reviews</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-C4V1L7GV-1</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - biotechnology & applied microbiology</json:string><json:string>2 - biochemical research methods</json:string></wos><scienceMetrix><json:string>1 - applied sciences</json:string><json:string>2 - enabling & strategic technologies</json:string><json:string>3 - biotechnology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Applied Microbiology and Biotechnology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences biologiques fondamentales et appliquees. psychologie</json:string><json:string>4 - protozoaires</json:string></inist></categories><publicationDate>2015</publicationDate><copyrightDate>2015</copyrightDate><doi><json:string>10.1002/biot.201400438</json:string></doi><id>B294EB921F41F8D7654A04E9AC4BE437F004790D</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><availability><licence>Copyright © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</licence></availability><date type="published" when="2015-05"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Rachael S.</forename><surname>Felberbaum</surname></persName><email>rfelberbaum@proteinsciences.com</email><affiliation><address><addrLine>Protein Sciences Corporation</addrLine><addrLine>Meriden, CT, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">B294EB921F41F8D7654A04E9AC4BE437F004790D</idno><idno type="ark">ark:/67375/WNG-C4V1L7GV-1</idno><idno type="DOI">10.1002/biot.201400438</idno><idno type="unit">BIOT201400438</idno><idno type="toTypesetVersion">file:BIOT.BIOT201400438.pdf</idno></analytic><monogr><title level="j" type="main">Biotechnology Journal</title><title level="j" type="sub">Vaccine Biotechnology</title><title level="j" type="alt">BIOTECHNOLOGY JOURNAL</title><idno type="pISSN">1860-6768</idno><idno type="eISSN">1860-7314</idno><idno type="book-DOI">10.1002/(ISSN)1860-7314</idno><idno type="book-part-DOI">10.1002/biot.v10.5</idno><idno type="product">BIOT</idno><imprint><biblScope unit="vol">10</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="702">702</biblScope><biblScope unit="page" to="714">714</biblScope><biblScope unit="page-count">13</biblScope><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2015-05"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.</p></abstract><abstract xml:lang="en" style="graphical"><p>The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.</p><p><figure type="box"><media mimeType="image" url="urn:x-wiley:18606768:media:BIOT201400438:content"></media></figure></p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">Adeno‐associated virus</term><term xml:id="kwd2">Baculovirus insect cell system</term><term xml:id="kwd3">Gene therapy vectors</term><term xml:id="kwd4">Influenza vaccine</term><term xml:id="kwd5">Viral vaccines</term></keywords><keywords rend="articleCategory"><term>Review</term></keywords><keywords rend="tocHeading1"><term>Reviews</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>WILEY‐VCH Verlag</publisherName><publisherLoc>Weinheim</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1860-7314</doi><issn type="print">1860-6768</issn><issn type="electronic">1860-7314</issn><idGroup><id type="product" value="BIOT"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="BIOTECHNOLOGY JOURNAL">Biotechnology Journal</title><title type="short">Biotechnology Journal</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/biot.v10.5</doi><titleGroup><title type="specialIssueTitle">Vaccine Biotechnology</title></titleGroup><numberingGroup><numbering type="journalVolume" number="10">10</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2015-05">May 2015</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="8" status="forIssue"><doi origin="wiley" registered="yes">10.1002/biot.201400438</doi><idGroup><id type="unit" value="BIOT201400438"></id></idGroup><countGroup><count type="pageTotal" number="13"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="publisher">Copyright © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</copyright><eventGroup><event type="manuscriptReceived" date="2014-09-16"></event><event type="manuscriptRevised" date="2015-01-12"></event><event type="manuscriptAccepted" date="2015-02-23"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.4.5 mode:FullText" date="2015-05-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.4.5 mode:FullText" date="2015-05-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2015-03-20"></event><event type="firstOnline" date="2015-03-20"></event><event type="publishedOnlineFinalForm" date="2015-05-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.7.2 mode:FullText" date="2016-01-05"></event></eventGroup><numberingGroup><numbering type="pageFirst">702</numbering><numbering type="pageLast">714</numbering></numberingGroup><correspondenceTo>Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:BIOT.BIOT201400438.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="117"></count></countGroup><titleGroup><title type="main" xml:lang="en">The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Rachael S.</givenNames><familyName>Felberbaum</familyName></personName><contactDetails><email>rfelberbaum@proteinsciences.com</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="US" type="organization"><unparsedAffiliation>Protein Sciences Corporation, Meriden, CT, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Adeno‐associated virus</keyword><keyword xml:id="kwd2">Baculovirus insect cell system</keyword><keyword xml:id="kwd3">Gene therapy vectors</keyword><keyword xml:id="kwd4">Influenza vaccine</keyword><keyword xml:id="kwd5">Viral vaccines</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.</p></abstract><abstract type="graphical" xml:lang="en"><p>The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.</p><p><blockFixed type="graphic"><mediaResourceGroup><mediaResource alt="image" href="urn:x-wiley:18606768:media:BIOT201400438:content" eRights="yes" copyright="WILEY‐VCH"></mediaResource></mediaResourceGroup></blockFixed></p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</title></titleInfo><name type="personal"><namePart type="given">Rachael S.</namePart><namePart type="family">Felberbaum</namePart><affiliation>Protein Sciences Corporation, Meriden, CT, USA</affiliation><affiliation>E-mail: rfelberbaum@proteinsciences.com</affiliation><affiliation>Correspondence address: Correspondence: Dr. Rachael Felberbaum, Senior Director, Business Development, Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450 USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>WILEY‐VCH Verlag</publisher><place><placeTerm type="text">Weinheim</placeTerm></place><dateIssued encoding="w3cdtf">2015-05</dateIssued><dateCaptured encoding="w3cdtf">2014-09-16</dateCaptured><dateValid encoding="w3cdtf">2015-02-23</dateValid><copyrightDate encoding="w3cdtf">2015</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">117</extent></physicalDescription><abstract lang="en">The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.</abstract><abstract type="graphical" lang="en">The baculovirus expression vector system (BEVS) has become an established commercial manufacturing platform. The authors review this technology, which enables fast, flexible and scalable protein production and is increasingly being used for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been licensed by global regulatory authorities, paving the way for new products that are in development.</abstract><subject lang="en"><genre>keywords</genre><topic>Adeno‐associated virus</topic><topic>Baculovirus insect cell system</topic><topic>Gene therapy vectors</topic><topic>Influenza vaccine</topic><topic>Viral vaccines</topic></subject><relatedItem type="host"><titleInfo><title>Biotechnology Journal</title></titleInfo><titleInfo type="abbreviated"><title>Biotechnology Journal</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Review</topic><topic>Reviews</topic></subject><identifier type="ISSN">1860-6768</identifier><identifier type="eISSN">1860-7314</identifier><identifier type="DOI">10.1002/(ISSN)1860-7314</identifier><identifier type="PublisherID">BIOT</identifier><part><date>2015</date><detail type="title"><title>Vaccine Biotechnology</title></detail><detail type="volume"><caption>vol.</caption><number>10</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>702</start><end>714</end><total>13</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Recombinant protein vaccines produced in insect cells.</title></titleInfo><name type="personal"><namePart type="given">M. M.</namePart><namePart type="family">Cox</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cox, M. M., Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30, 1759–1766.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1759</start><end>1766</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1759</start><end>1766</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Vaccines for viral and parasitic diseases produced with baculovirus vectors.</title></titleInfo><name type="personal"><namePart type="given">M. M.</namePart><namePart type="family">van Oers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">van Oers, M. M., Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv. Virus Res. 2006, 68, 193–253.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>193</start><end>253</end></extent></part><relatedItem type="host"><titleInfo><title>Adv. Virus Res.</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>193</start><end>253</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Cox, M. M., Commercial production in insect cells. One company's perspective. BioProcess Int. 2004, 1–5.</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Production of recombinant proteins by microbes and higher organisms.</title></titleInfo><name type="personal"><namePart type="given">A. L.</namePart><namePart type="family">Demain</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Vaishnav</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Demain, A. L., Vaishnav, P., Production of recombinant proteins by microbes and higher organisms. Biotechnol. Adv. 2009, 27, 297–306.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>297</start><end>306</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnol. Adv.</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>297</start><end>306</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>A fast track influenza virus vaccine produced in insect cells.</title></titleInfo><name type="personal"><namePart type="given">M. M.</namePart><namePart type="family">Cox</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Hashimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cox, M. M., Hashimoto, Y., A fast track influenza virus vaccine produced in insect cells. J. Invertebr. Pathol. 2011, 107Suppl., S31–41.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>107Suppl.</number></detail><extent unit="pages"><start>31</start><end>41</end></extent></part><relatedItem type="host"><titleInfo><title>J. Invertebr. Pathol.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>107Suppl.</number></detail><extent unit="pages"><start>31</start><end>41</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Insect cell technology is a versatile and robust vaccine manufacturing platform.</title></titleInfo><name type="personal"><namePart type="given">J. A.</namePart><namePart type="family">Mena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. A.</namePart><namePart type="family">Kamen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mena, J. A., Kamen, A. A., Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev. Vaccines 2011, 10, 1063–1081.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1063</start><end>1081</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev. Vaccines</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1063</start><end>1081</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Opportunities and challenges for the baculovirus expression system.</title></titleInfo><name type="personal"><namePart type="given">M. M.</namePart><namePart type="family">van Oers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">van Oers, M. M., Opportunities and challenges for the baculovirus expression system. J. Invertebr. Pathol. 2011, 107Suppl., S3–15.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>107Suppl.</number></detail><extent unit="pages"><start>3</start><end>15</end></extent></part><relatedItem type="host"><titleInfo><title>J. Invertebr. Pathol.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>107Suppl.</number></detail><extent unit="pages"><start>3</start><end>15</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Baculovirus‐insect cell expression systems.</title></titleInfo><name type="personal"><namePart type="given">D. L.</namePart><namePart type="family">Jarvis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jarvis, D. L., Baculovirus‐insect cell expression systems. Methods Enzymol. 2009, 463, 191–222.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>463</number></detail><extent unit="pages"><start>191</start><end>222</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Enzymol.</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>463</number></detail><extent unit="pages"><start>191</start><end>222</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Baculovirus as a highly efficient expression vector in insect and mammalian cells.</title></titleInfo><name type="personal"><namePart type="given">Y. C.</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hu, Y. C., Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacol. Sin. 2005, 26, 405–416.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>405</start><end>416</end></extent></part><relatedItem type="host"><titleInfo><title>Acta Pharmacol. Sin.</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>405</start><end>416</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>The complete DNA sequence of Autographa californica nuclear polyhedrosis virus.</title></titleInfo><name type="personal"><namePart type="given">M. D.</namePart><namePart type="family">Ayres</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. C.</namePart><namePart type="family">Howard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Kuzio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Lopez‐Ferber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. D.</namePart><namePart type="family">Possee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ayres, M. D., Howard, S. C., Kuzio, J., Lopez‐Ferber, M., Possee, R. D., The complete DNA sequence of Autographa californica nuclear polyhedrosis virus. Virology 1994, 202, 586–605.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>202</number></detail><extent unit="pages"><start>586</start><end>605</end></extent></part><relatedItem type="host"><titleInfo><title>Virology</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>202</number></detail><extent unit="pages"><start>586</start><end>605</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Production of human beta interferon in insect cells infected with a baculovirus expression vector.</title></titleInfo><name type="personal"><namePart type="given">G. E.</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. D.</namePart><namePart type="family">Summers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. J.</namePart><namePart type="family">Fraser</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith, G. E., Summers, M. D., Fraser, M. J., Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol. Cell. Biol. 1983, 3, 2156–2165.</note><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>2156</start><end>2165</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Cell. Biol.</title></titleInfo><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>2156</start><end>2165</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>A baculovirus dual expression vector derived from the Autographa californica nuclear polyhedrosis virus polyhedrin and p10 promoters: Co‐expression of two influenza virus genes in insect cells.</title></titleInfo><name type="personal"><namePart type="given">U.</namePart><namePart type="family">Weyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. D.</namePart><namePart type="family">Possee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weyer, U., Possee, R. D., A baculovirus dual expression vector derived from the Autographa californica nuclear polyhedrosis virus polyhedrin and p10 promoters: Co‐expression of two influenza virus genes in insect cells. J. Gen. Virol. 1991, 72(Pt12), 2967–2974.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>72(Pt12)</number></detail><extent unit="pages"><start>2967</start><end>2974</end></extent></part><relatedItem type="host"><titleInfo><title>J. Gen. Virol.</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>72(Pt12)</number></detail><extent unit="pages"><start>2967</start><end>2974</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>A method for producing recombinant baculovirus expression vectors at high frequency.</title></titleInfo><name type="personal"><namePart type="given">P. A.</namePart><namePart type="family">Kitts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. D.</namePart><namePart type="family">Possee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kitts, P. A., Possee, R. D., A method for producing recombinant baculovirus expression vectors at high frequency. Biotechniques 1993, 14, 810–817.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>810</start><end>817</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechniques</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>810</start><end>817</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Spontaneous excision of BAC vector sequences from bacmid‐derived baculovirus expression vectors upon passage in insect cells.</title></titleInfo><name type="personal"><namePart type="given">G. P.</namePart><namePart type="family">Pijlman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pijlman, G. P., Spontaneous excision of BAC vector sequences from bacmid‐derived baculovirus expression vectors upon passage in insect cells. J. Gen. Virol. 2003, 84, 2669–2678.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>2669</start><end>2678</end></extent></part><relatedItem type="host"><titleInfo><title>J. Gen. Virol.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>2669</start><end>2678</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Vaughn, J. L., Goodwin, R. H., Tompkins, G. J., McCawley, P., The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae). In vitro 1977, 13, 213–217.</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Screening of insect cell lines for the production of recombinant proteins and infectious virus in the baculovirus expression system.</title></titleInfo><name type="personal"><namePart type="given">T. J.</namePart><namePart type="family">Wickham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Davis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. R.</namePart><namePart type="family">Granados</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. L.</namePart><namePart type="family">Shuler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H. A.</namePart><namePart type="family">Wood</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wickham, T. J., Davis, T., Granados, R. R., Shuler, M. L., Wood, H. A., Screening of insect cell lines for the production of recombinant proteins and infectious virus in the baculovirus expression system. Biotechnol. Prog. 1992, 8, 391–396.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>391</start><end>396</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnol. Prog.</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>391</start><end>396</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Traditional and new influenza vaccines.</title></titleInfo><name type="personal"><namePart type="given">S. S.</namePart><namePart type="family">Wong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. J.</namePart><namePart type="family">Webby</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wong, S. S., Webby, R. J., Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26, 476–492.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>476</start><end>492</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Microbiol. Rev.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>476</start><end>492</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Molecular mechanisms enhancing the proteome of influenza A viruses: An overview of recently discovered proteins.</title></titleInfo><name type="personal"><namePart type="given">A. V.</namePart><namePart type="family">Vasin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O. A.</namePart><namePart type="family">Temkina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V. V.</namePart><namePart type="family">Egorov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. A.</namePart><namePart type="family">Klotchenko</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vasin, A. V., Temkina, O. A., Egorov, V. V., Klotchenko, S. A. et al., Molecular mechanisms enhancing the proteome of influenza A viruses: An overview of recently discovered proteins. Virus Res. 2014, 185, 53–63.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>185</number></detail><extent unit="pages"><start>53</start><end>63</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Res.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>185</number></detail><extent unit="pages"><start>53</start><end>63</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg‐adapted H3N2 vaccine strain not antigenic drift in circulating viruses.</title></titleInfo><name type="personal"><namePart type="given">D. M.</namePart><namePart type="family">Skowronski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N. Z.</namePart><namePart type="family">Janjua</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">De Serres</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Sabaiduc</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Skowronski, D. M., Janjua, N. Z., De Serres, G., Sabaiduc, S. et al., Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg‐adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014, 9, e92153.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e92153</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e92153</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Mechanism of a decrease in potency for the recombinant influenza a virus hemagglutinin H3 antigen during storage.</title></titleInfo><name type="personal"><namePart type="given">J. M.</namePart><namePart type="family">Hickey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K. M.</namePart><namePart type="family">Holtz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Manikwar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. B.</namePart><namePart type="family">Joshi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hickey, J. M., Holtz, K. M., Manikwar, P., Joshi, S. B. et al., Mechanism of a decrease in potency for the recombinant influenza a virus hemagglutinin H3 antigen during storage. J. Pharm. Sci. 2014, 103, 821–827.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>821</start><end>827</end></extent></part><relatedItem type="host"><titleInfo><title>J. Pharm. Sci.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>821</start><end>827</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevents cross‐linked multimer formation and potency loss.</title></titleInfo><name type="personal"><namePart type="given">K. M.</namePart><namePart type="family">Holtz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. S.</namePart><namePart type="family">Robinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E. E.</namePart><namePart type="family">Matthews</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Hashimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holtz, K. M., Robinson, P. S., Matthews, E. E., Hashimoto, Y. et al., Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevents cross‐linked multimer formation and potency loss. BMC Biotech. 2014, 14, 1.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Biotech.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Grohskopf, L. A., Shay, D. K., Shimabukuro, T. T., Sokolow, L. Z. et al., Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices – United States, 2013–2014. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 2013, 62, 1–43.</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Antigenic and genetic characteristics of swine‐origin 2009 A(H1N1) influenza viruses circulating in humans.</title></titleInfo><name type="personal"><namePart type="given">R. J.</namePart><namePart type="family">Garten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. T.</namePart><namePart type="family">Davis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. A.</namePart><namePart type="family">Russell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Shu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Garten, R. J., Davis, C. T., Russell, C. A., Shu, B. et al., Antigenic and genetic characteristics of swine‐origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325, 197–201.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>325</number></detail><extent unit="pages"><start>197</start><end>201</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>325</number></detail><extent unit="pages"><start>197</start><end>201</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Pandemic novel 2009 H1N1 influenza: What have we learned?</title></titleInfo><name type="personal"><namePart type="given">P.</namePart><namePart type="family">LaRussa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">LaRussa, P., Pandemic novel 2009 H1N1 influenza: What have we learned? Semin. Respir. Crit. Care Med. 2011, 32, 393–399.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>393</start><end>399</end></extent></part><relatedItem type="host"><titleInfo><title>Semin. Respir. Crit. Care Med.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>393</start><end>399</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Impact of influenza B lineage‐level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999‐2012.</title></titleInfo><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Heikkinen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Ikonen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Ziegler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heikkinen, T., Ikonen, N., Ziegler, T., Impact of influenza B lineage‐level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999‐2012. Clin. Infect. Dis. 2014, 59(11), 1519–1524.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>59(11)</number></detail><extent unit="pages"><start>1519</start><end>1524</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Infect. Dis.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>59(11)</number></detail><extent unit="pages"><start>1519</start><end>1524</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Influenza vaccine: The challenge of antigenic drift.</title></titleInfo><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Carrat</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Flahault</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carrat, F., Flahault, A., Influenza vaccine: The challenge of antigenic drift. Vaccine 2007, 25, 6852–6862.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>6852</start><end>6862</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>6852</start><end>6862</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Vaccine allergy.</title></titleInfo><name type="personal"><namePart type="given">J. C.</namePart><namePart type="family">Caubet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Ponvert</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Caubet, J. C., Ponvert, C., Vaccine allergy. Immunol. Allergy Clin. of North Am. 2014, 34, 597–613, ix.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>597</start><end>613</end></extent></part><relatedItem type="host"><titleInfo><title>Immunol. Allergy Clin. of North Am.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>597</start><end>613</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Molecular and structural characterization of the L1 virus‐like particles that are used as vaccine antigens in Cervarix, the AS04‐adjuvanted HPV‐16 and ‐18 cervical cancer vaccine.</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Deschuyteneer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Elouahabi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Plainchamp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Plisnier</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Deschuyteneer, M., Elouahabi, A., Plainchamp, D., Plisnier, M. et al., Molecular and structural characterization of the L1 virus‐like particles that are used as vaccine antigens in Cervarix, the AS04‐adjuvanted HPV‐16 and ‐18 cervical cancer vaccine. Hum. Vaccin. 2010, 6, 407–419.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>407</start><end>419</end></extent></part><relatedItem type="host"><titleInfo><title>Hum. Vaccin.</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>407</start><end>419</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>A recombinant baculovirus‐expressed S glycoprotein vaccine elicits high titers of SARS‐associated coronavirus (SARS‐CoV) neutralizing antibodies in mice.</title></titleInfo><name type="personal"><namePart type="given">Z.</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Post</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Chubet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Holtz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhou, Z., Post, P., Chubet, R., Holtz, K. et al., A recombinant baculovirus‐expressed S glycoprotein vaccine elicits high titers of SARS‐associated coronavirus (SARS‐CoV) neutralizing antibodies in mice. Vaccine 2006, 24, 3624–3631.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>3624</start><end>3631</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>3624</start><end>3631</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>A designer hyper interleukin 11 (H11) is a biologically active cytokine.</title></titleInfo><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Dams‐Kozlowska</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Gryska</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Kwiatkowska‐Borowczyk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Izycki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dams‐Kozlowska, H., Gryska, K., Kwiatkowska‐Borowczyk, E., Izycki, D. et al., A designer hyper interleukin 11 (H11) is a biologically active cytokine. BMC Biotech. 2012, 12, 8.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>8</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Biotech.</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>8</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross‐neutralizing antibodies and protective immunity against divergent human papillomavirus types.</title></titleInfo><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen, X., Liu, H., Zhang, T., Liu, Y. et al., A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross‐neutralizing antibodies and protective immunity against divergent human papillomavirus types. PLoS One 2014, 9, e95448.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e95448</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e95448</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Baculovirus vector as an avian influenza vaccine: Hemagglutinin expression and presentation augment the vaccine immunogenicity.</title></titleInfo><name type="personal"><namePart type="given">C. Y.</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. Y.</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. C.</namePart><namePart type="family">Cheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. P.</namePart><namePart type="family">Tsai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen, C. Y., Lin, S. Y., Cheng, M. C., Tsai, C. P. et al., Baculovirus vector as an avian influenza vaccine: Hemagglutinin expression and presentation augment the vaccine immunogenicity. J. Biotechnol. 2013, 164, 143–150.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>143</start><end>150</end></extent></part><relatedItem type="host"><titleInfo><title>J. Biotechnol.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>143</start><end>150</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>PROVENGE (Sipuleucel‐T) in prostate cancer: The first FDA‐approved therapeutic cancer vaccine.</title></titleInfo><name type="personal"><namePart type="given">M. A.</namePart><namePart type="family">Cheever</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. S.</namePart><namePart type="family">Higano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cheever, M. A., Higano, C. S., PROVENGE (Sipuleucel‐T) in prostate cancer: The first FDA‐approved therapeutic cancer vaccine. Clin. Cancer Res. 2011, 17, 3520–3526.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>3520</start><end>3526</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Cancer Res.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>3520</start><end>3526</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>The presence of nuclear polyhedrosis viruses of Trichoplusia ni on cabbage from the market shelf.</title></titleInfo><name type="personal"><namePart type="given">A. M.</namePart><namePart type="family">Heimpel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E. D.</namePart><namePart type="family">Thomas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. R.</namePart><namePart type="family">Adams</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L. J.</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heimpel, A. M., Thomas, E. D., Adams, J. R., Smith, L. J., The presence of nuclear polyhedrosis viruses of Trichoplusia ni on cabbage from the market shelf. Environmental Entomology 1973, 2, 72–75.</note><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>72</start><end>75</end></extent></part><relatedItem type="host"><titleInfo><title>Environmental Entomology</title></titleInfo><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>72</start><end>75</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>In vitro survey of Autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells.</title></titleInfo><name type="personal"><namePart type="given">L. E.</namePart><namePart type="family">Volkman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. A.</namePart><namePart type="family">Goldsmith</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Volkman, L. E., Goldsmith, P. A., In vitro survey of Autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells. Appl. Environ. Microbiol. 1983, 45, 1085–1093.</note><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1085</start><end>1093</end></extent></part><relatedItem type="host"><titleInfo><title>Appl. Environ. Microbiol.</title></titleInfo><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1085</start><end>1093</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Baculovirus‐mediated expression of bacterial genes in dipteran and mammalian cells.</title></titleInfo><name type="personal"><namePart type="given">L. F.</namePart><namePart type="family">Carbonell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. J.</namePart><namePart type="family">Klowden</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L. K.</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carbonell, L. F., Klowden, M. J., Miller, L. K., Baculovirus‐mediated expression of bacterial genes in dipteran and mammalian cells. J. Virol. 1985, 56, 153–160.</note><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>153</start><end>160</end></extent></part><relatedItem type="host"><titleInfo><title>J. Virol.</title></titleInfo><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>153</start><end>160</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Efficient gene transfer into human hepatocytes by baculovirus vectors.</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Hofmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Sandig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Jennings</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Rudolph</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hofmann, C., Sandig, V., Jennings, G., Rudolph, M. et al., Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 10099–10103.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>10099</start><end>10103</end></extent></part><relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U. S. A.</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>10099</start><end>10103</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Baculovirus‐mediated gene transfer into mammalian cells.</title></titleInfo><name type="personal"><namePart type="given">F. M.</namePart><namePart type="family">Boyce</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N. L.</namePart><namePart type="family">Bucher</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boyce, F. M., Bucher, N. L., Baculovirus‐mediated gene transfer into mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 2348–2352.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>2348</start><end>2352</end></extent></part><relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U. S. A.</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>93</number></detail><extent unit="pages"><start>2348</start><end>2352</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Arbovirus vaccines; opportunities for the baculovirus‐insect cell expression system.</title></titleInfo><name type="personal"><namePart type="given">S. W.</namePart><namePart type="family">Metz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G. P.</namePart><namePart type="family">Pijlman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Metz, S. W., Pijlman, G. P., Arbovirus vaccines; opportunities for the baculovirus‐insect cell expression system. J. Invertebr. Pathol. 2011, 107Suppl., S16–30.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>107Suppl.</number></detail><extent unit="pages"><start>16</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>J. Invertebr. Pathol.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>107Suppl.</number></detail><extent unit="pages"><start>16</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Latent infection of a new alphanodavirus in an insect cell line.</title></titleInfo><name type="personal"><namePart type="given">T. C.</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. D.</namePart><namePart type="family">Scotti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Miyamura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Takeda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Li, T. C., Scotti, P. D., Miyamura, T., Takeda, N., Latent infection of a new alphanodavirus in an insect cell line. J. Virol. 2007, 81, 10890–10896.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>10890</start><end>10896</end></extent></part><relatedItem type="host"><titleInfo><title>J. Virol.</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>10890</start><end>10896</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Gypsy endogenous retrovirus maintains potential infectivity in several species of Drosophilids.</title></titleInfo><name type="personal"><namePart type="given">J. V.</namePart><namePart type="family">Llorens</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. B.</namePart><namePart type="family">Clark</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Martinez‐Garay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Soriano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Llorens, J. V., Clark, J. B., Martinez‐Garay, I., Soriano, S. et al., Gypsy endogenous retrovirus maintains potential infectivity in several species of Drosophilids. BMC Evol. Biol. 2008, 8, 302.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>302</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Evol. Biol.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>302</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines.</title></titleInfo><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Ma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T. A.</namePart><namePart type="family">Galvin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. R.</namePart><namePart type="family">Glasner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Shaheduzzaman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. S.</namePart><namePart type="family">Khan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ma, H., Galvin, T. A., Glasner, D. R., Shaheduzzaman, S., Khan, A. S., Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines. J. Virol. 2014, 88, 6576–6585.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>6576</start><end>6585</end></extent></part><relatedItem type="host"><titleInfo><title>J. Virol.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>6576</start><end>6585</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Mammalian stable expression of biotherapeutics.</title></titleInfo><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Jostock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H. P.</namePart><namePart type="family">Knopf</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jostock, T., Knopf, H. P., Mammalian stable expression of biotherapeutics. Methods Mol. Biol. 2012, 899, 227–238.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>899</number></detail><extent unit="pages"><start>227</start><end>238</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Mol. Biol.</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>899</number></detail><extent unit="pages"><start>227</start><end>238</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Buckland, B., Boulanger, R., Fino, M., Srivastava, I. et al., Technology transfer and scale‐up of the Flublok® recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine 2014.</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Vaccine process technology.</title></titleInfo><name type="personal"><namePart type="given">J. O.</namePart><namePart type="family">Josefsberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Buckland</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Josefsberg, J. O., Buckland, B., Vaccine process technology. Biotechnol. Bioeng. 2012, 109, 1443–1460.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>1443</start><end>1460</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnol. Bioeng.</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>1443</start><end>1460</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Thirty years of baculovirus‐insect cell protein expression: From dark horse to mainstream technology.</title></titleInfo><name type="personal"><namePart type="given">M. M.</namePart><namePart type="family">van Oers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G. P.</namePart><namePart type="family">Pijlman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. M.</namePart><namePart type="family">Vlak</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">van Oers, M. M., Pijlman, G. P., Vlak, J. M., Thirty years of baculovirus‐insect cell protein expression: From dark horse to mainstream technology. J. Gen. Virol. 2015, 96, 6–23.</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>6</start><end>23</end></extent></part><relatedItem type="host"><titleInfo><title>J. Gen. Virol.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>6</start><end>23</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Baculovirus as versatile vectors for protein expression in insect and mammalian cells.</title></titleInfo><name type="personal"><namePart type="given">T. A.</namePart><namePart type="family">Kost</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. P.</namePart><namePart type="family">Condreay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. L.</namePart><namePart type="family">Jarvis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kost, T. A., Condreay, J. P., Jarvis, D. L., Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 2005, 23, 567–575.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>567</start><end>575</end></extent></part><relatedItem type="host"><titleInfo><title>Nat. Biotechnol.</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>567</start><end>575</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Transforming lepidopteran insect cells for improved protein processing.</title></titleInfo><name type="personal"><namePart type="given">R. L.</namePart><namePart type="family">Harrison</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. L.</namePart><namePart type="family">Jarvis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harrison, R. L., Jarvis, D. L., Transforming lepidopteran insect cells for improved protein processing. Methods Mol. Biol. 2007, 388, 341–356.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>388</number></detail><extent unit="pages"><start>341</start><end>356</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Mol. Biol.</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>388</number></detail><extent unit="pages"><start>341</start><end>356</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>N‐Glycosylation engineering of lepidopteran insect cells by the introduction of the beta1,4‐N‐acetylglucosaminyltransferase III gene.</title></titleInfo><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Okada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Ihara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Ito</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Nakano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Okada, T., Ihara, H., Ito, R., Nakano, M. et al., N‐Glycosylation engineering of lepidopteran insect cells by the introduction of the beta1,4‐N‐acetylglucosaminyltransferase III gene. Glycobiology 2010, 20, 1147–1159.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1147</start><end>1159</end></extent></part><relatedItem type="host"><titleInfo><title>Glycobiology</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1147</start><end>1159</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>A transgenic insect cell line engineered to produce CMP‐sialic acid and sialylated glycoproteins.</title></titleInfo><name type="personal"><namePart type="given">J. J.</namePart><namePart type="family">Aumiller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. R.</namePart><namePart type="family">Hollister</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. L.</namePart><namePart type="family">Jarvis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aumiller, J. J., Hollister, J. R., Jarvis, D. L., A transgenic insect cell line engineered to produce CMP‐sialic acid and sialylated glycoproteins. Glycobiology 2003, 13, 497–507.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>497</start><end>507</end></extent></part><relatedItem type="host"><titleInfo><title>Glycobiology</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>497</start><end>507</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>SweetBac: A new approach for the production of mammalianised glycoproteins in insect cells.</title></titleInfo><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Palmberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I. B.</namePart><namePart type="family">Wilson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Berger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Grabherr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Rendic</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Palmberger, D., Wilson, I. B., Berger, I., Grabherr, R., Rendic, D., SweetBac: A new approach for the production of mammalianised glycoproteins in insect cells. PLoS One 2012, 7, e34226.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>e34226</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>e34226</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Recombinant adeno‐associated virus transduction and integration.</title></titleInfo><name type="personal"><namePart type="given">B. R.</namePart><namePart type="family">Schultz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. S.</namePart><namePart type="family">Chamberlain</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schultz, B. R., Chamberlain, J. S., Recombinant adeno‐associated virus transduction and integration. Mol. Ther. 2008, 16, 1189–1199.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1189</start><end>1199</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Ther.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1189</start><end>1199</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>New developments in the use of gene therapy to treat Duchenne muscular dystrophy.</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Jarmin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Kymalainen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Popplewell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Dickson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jarmin, S., Kymalainen, H., Popplewell, L., Dickson, G., New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin. Biol. Ther. 2014, 14, 209–230.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>209</start><end>230</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Opin. Biol. Ther.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>209</start><end>230</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection.</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Zincarelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Soltys</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Rengo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. E.</namePart><namePart type="family">Rabinowitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zincarelli, C., Soltys, S., Rengo, G., Rabinowitz, J. E., Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 2008, 16, 1073–1080.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1073</start><end>1080</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Ther.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1073</start><end>1080</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Insect cells as a factory to produce adeno‐associated virus type 2 vectors.</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Urabe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Ding</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. M.</namePart><namePart type="family">Kotin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Urabe, M., Ding, C., Kotin, R. M., Insect cells as a factory to produce adeno‐associated virus type 2 vectors. Hum. Gene Ther. 2002, 13, 1935–1943.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1935</start><end>1943</end></extent></part><relatedItem type="host"><titleInfo><title>Hum. Gene Ther.</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1935</start><end>1943</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>A simplified baculovirus‐AAV expression vector system coupled with one‐step affinity purification yields high‐titer rAAV stocks from insect cells.</title></titleInfo><name type="personal"><namePart type="given">R. H.</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. R.</namePart><namePart type="family">Levy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. M.</namePart><namePart type="family">Kotin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith, R. H., Levy, J. R., Kotin, R. M., A simplified baculovirus‐AAV expression vector system coupled with one‐step affinity purification yields high‐titer rAAV stocks from insect cells. Mol. Ther. 2009, 17, 1888–1896.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>1888</start><end>1896</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Ther.</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>1888</start><end>1896</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>Improving adeno‐associated vector yield in high density insect cell cultures.</title></titleInfo><name type="personal"><namePart type="given">J. A.</namePart><namePart type="family">Mena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. G.</namePart><namePart type="family">Aucoin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Montes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. S.</namePart><namePart type="family">Chahal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. A.</namePart><namePart type="family">Kamen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mena, J. A., Aucoin, M. G., Montes, J., Chahal, P. S., Kamen, A. A., Improving adeno‐associated vector yield in high density insect cell cultures. J. Gene Med. 2010, 12, 157–167.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>157</start><end>167</end></extent></part><relatedItem type="host"><titleInfo><title>J. Gene Med.</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>157</start><end>167</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system.</title></titleInfo><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Kohlbrenner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Aslanidi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Nash</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Shklyaev</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kohlbrenner, E., Aslanidi, G., Nash, K., Shklyaev, S. et al., Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 2005, 12, 1217–1225.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>1217</start><end>1225</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Ther.</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>1217</start><end>1225</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Economized large‐scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system.</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Negrete</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L. C.</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. F.</namePart><namePart type="family">Mendez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. R.</namePart><namePart type="family">Levy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. M.</namePart><namePart type="family">Kotin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Negrete, A., Yang, L. C., Mendez, A. F., Levy, J. R., Kotin, R. M., Economized large‐scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J. Gene Med. 2007, 9, 938–948.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>938</start><end>948</end></extent></part><relatedItem type="host"><titleInfo><title>J. Gene Med.</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>938</start><end>948</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>Removal of empty capsids from type 1 adeno‐associated virus vector stocks by anion‐exchange chromatography potentiates transgene expression.</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Urabe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K. Q.</namePart><namePart type="family">Xin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Obara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Nakakura</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Urabe, M., Xin, K. Q., Obara, Y., Nakakura, T. et al., Removal of empty capsids from type 1 adeno‐associated virus vector stocks by anion‐exchange chromatography potentiates transgene expression. Mol. Ther. 2006, 13, 823–828.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>823</start><end>828</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Ther.</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>823</start><end>828</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>Toward exascale production of recombinant adeno‐associated virus for gene transfer applications.</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Cecchini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Negrete</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. M.</namePart><namePart type="family">Kotin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cecchini, S., Negrete, A., Kotin, R. M., Toward exascale production of recombinant adeno‐associated virus for gene transfer applications. Gene Ther. 2008, 15, 823–830.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>823</start><end>830</end></extent></part><relatedItem type="host"><titleInfo><title>Gene Ther.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>823</start><end>830</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Producing recombinant adeno‐associated virus in foster cells: Overcoming production limitations using a baculovirus‐insect cell expression strategy.</title></titleInfo><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Virag</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Cecchini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. M.</namePart><namePart type="family">Kotin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Virag, T., Cecchini, S., Kotin, R. M., Producing recombinant adeno‐associated virus in foster cells: Overcoming production limitations using a baculovirus‐insect cell expression strategy. Hum. Gene Ther. 2009, 20, 807–817.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>807</start><end>817</end></extent></part><relatedItem type="host"><titleInfo><title>Hum. Gene Ther.</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>807</start><end>817</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Large‐scale production of recombinant adeno‐associated viral vectors.</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Negrete</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. M.</namePart><namePart type="family">Kotin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Negrete, A., Kotin, R. M., Large‐scale production of recombinant adeno‐associated viral vectors. Methods Mol. Biol. 2008, 433, 79–96.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>433</number></detail><extent unit="pages"><start>79</start><end>96</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Mol. Biol.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>433</number></detail><extent unit="pages"><start>79</start><end>96</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>Novel tools for production and purification of recombinant adenoassociated virus vectors.</title></titleInfo><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Grimm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Kern</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Rittner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. A.</namePart><namePart type="family">Kleinschmidt</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grimm, D., Kern, A., Rittner, K., Kleinschmidt, J. A., Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 1998, 9, 2745–2760.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>2745</start><end>2760</end></extent></part><relatedItem type="host"><titleInfo><title>Hum. Gene Ther.</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>2745</start><end>2760</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>Adeno‐associated virus as a gene therapy vector: Vector development, production and clinical applications.</title></titleInfo><name type="personal"><namePart type="given">J. C.</namePart><namePart type="family">Grieger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. J.</namePart><namePart type="family">Samulski</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grieger, J. C., Samulski, R. J., Adeno‐associated virus as a gene therapy vector: Vector development, production and clinical applications. Adv. Biochem. Eng./Biotechnol. 2005, 99, 119–145.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>119</start><end>145</end></extent></part><relatedItem type="host"><titleInfo><title>Adv. Biochem. Eng./Biotechnol.</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>119</start><end>145</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Immune responses to AAV‐vectors, the glybera example from bench to bedside.</title></titleInfo><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Ferreira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Petry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Salmon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ferreira, V., Petry, H., Salmon, F., Immune responses to AAV‐vectors, the glybera example from bench to bedside. Front. Immunol. 2014, 5, 82.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>82</start></extent></part><relatedItem type="host"><titleInfo><title>Front. Immunol.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>82</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>Safety profile of recombinant adeno‐associated viral vectors: Focus on alipogene tiparvovec (Glybera®).</title></titleInfo><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Salmon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Grosios</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Petry</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Salmon, F., Grosios, K., Petry, H., Safety profile of recombinant adeno‐associated viral vectors: Focus on alipogene tiparvovec (Glybera®). Expert Rev. Clin. Pharmacol. 2014, 7, 53–65.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>53</start><end>65</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev. Clin. Pharmacol.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>53</start><end>65</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>Identification of sequence variants in genetic disease‐causing genes using targeted next‐generation sequencing.</title></titleInfo><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Wei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Ju</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Yi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Zhu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wei, X., Ju, X., Yi, X., Zhu, Q. et al., Identification of sequence variants in genetic disease‐causing genes using targeted next‐generation sequencing. PLoS One 2011, 6, e29500.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>e29500</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>e29500</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Current status of haemophilia gene therapy.</title></titleInfo><name type="personal"><namePart type="given">K. H.</namePart><namePart type="family">High</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Nathwani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Spencer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Lillicrap</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">High, K. H., Nathwani, A., Spencer, T., Lillicrap, D., Current status of haemophilia gene therapy. Haemophilia 2014, 20, 4, 43–49.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>43</start><end>49</end></extent></part><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>43</start><end>49</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>Advances in AAV vector development for gene therapy in the retina.</title></titleInfo><name type="personal"><namePart type="given">T. P.</namePart><namePart type="family">Day</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L. C.</namePart><namePart type="family">Byrne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. V.</namePart><namePart type="family">Schaffer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. G.</namePart><namePart type="family">Flannery</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Day, T. P., Byrne, L. C., Schaffer, D. V., Flannery, J. G., Advances in AAV vector development for gene therapy in the retina. Adv. Exp. Med. Biol. 2014, 801, 687–693.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>801</number></detail><extent unit="pages"><start>687</start><end>693</end></extent></part><relatedItem type="host"><titleInfo><title>Adv. Exp. Med. Biol.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>801</number></detail><extent unit="pages"><start>687</start><end>693</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Preclinical safety evaluation of AAV2‐sFLT01‐ a gene therapy for age‐related macular degeneration.</title></titleInfo><name type="personal"><namePart type="given">T. K.</namePart><namePart type="family">Maclachlan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Lukason</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Collins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Munger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maclachlan, T. K., Lukason, M., Collins, M., Munger, R. et al., Preclinical safety evaluation of AAV2‐sFLT01‐ a gene therapy for age‐related macular degeneration. Mol. Ther. 2011, 19, 326–334.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>326</start><end>334</end></extent></part><relatedItem type="host"><titleInfo><title>Mol. Ther.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>326</start><end>334</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit72"><titleInfo><title>Adeno‐associated virus (AAV) gene therapy for neurological disease.</title></titleInfo><name type="personal"><namePart type="given">M. S.</namePart><namePart type="family">Weinberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. J.</namePart><namePart type="family">Samulski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T. J.</namePart><namePart type="family">McCown</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weinberg, M. S., Samulski, R. J., McCown, T. J., Adeno‐associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 2013, 69, 82–88.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>82</start><end>88</end></extent></part><relatedItem type="host"><titleInfo><title>Neuropharmacology</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>82</start><end>88</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit73"><titleInfo><title>Full‐length dystrophin reconstitution with adeno‐associated viral vectors.</title></titleInfo><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Lostal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Kodippili</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Yue</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Duan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lostal, W., Kodippili, K., Yue, Y., Duan, D., Full‐length dystrophin reconstitution with adeno‐associated viral vectors. Hum. Gene Ther. 2014, 25, 552–562.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>552</start><end>562</end></extent></part><relatedItem type="host"><titleInfo><title>Hum. Gene Ther.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>552</start><end>562</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit74"><titleInfo><title>Recombinant trivalent influenza vaccine (Flublok®): A review of its use in the prevention of seasonal influenza in adults.</title></titleInfo><name type="personal"><namePart type="given">L. P.</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yang, L. P., Recombinant trivalent influenza vaccine (Flublok®): A review of its use in the prevention of seasonal influenza in adults. Drugs 2013, 73, 1357–1366.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>1357</start><end>1366</end></extent></part><relatedItem type="host"><titleInfo><title>Drugs</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>1357</start><end>1366</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit75"><titleInfo><title>Pandemic influenza vaccine: Characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.</title></titleInfo><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Feshchenko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. G.</namePart><namePart type="family">Rhodes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Felberbaum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">McPherson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feshchenko, E., Rhodes, D. G., Felberbaum, R., McPherson, C. et al., Pandemic influenza vaccine: Characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMCBiotech. 2012, 12, 77.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>77</start></extent></part><relatedItem type="host"><titleInfo><title>BMCBiotech.</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>77</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit76"><titleInfo><title>Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo‐controlled trial.</title></titleInfo><name type="personal"><namePart type="given">J. J.</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">El Sahly</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">King</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Graham</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Treanor, J. J., El Sahly, H., King, J., Graham, I. et al., Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo‐controlled trial. Vaccine 2011, 29, 7733–7739.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>7733</start><end>7739</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>7733</start><end>7739</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit77"><titleInfo><title>Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus‐expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age.</title></titleInfo><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Baxter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. A.</namePart><namePart type="family">Patriarca</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Ensor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Izikson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baxter, R., Patriarca, P. A., Ensor, K., Izikson, R. et al., Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus‐expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 2011, 29, 2272–2278.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>2272</start><end>2278</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>2272</start><end>2278</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit78"><titleInfo><title>Safety and immunogenicity of a baculovirus‐expressed hemagglutinin influenza vaccine: A randomized controlled trial.</title></titleInfo><name type="personal"><namePart type="given">J. J.</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G. M.</namePart><namePart type="family">Schiff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F. G.</namePart><namePart type="family">Hayden</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. C.</namePart><namePart type="family">Brady</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Treanor, J. J., Schiff, G. M., Hayden, F. G., Brady, R. C. et al., Safety and immunogenicity of a baculovirus‐expressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA 2007, 297, 1577–1582.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>297</number></detail><extent unit="pages"><start>1577</start><end>1582</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>297</number></detail><extent unit="pages"><start>1577</start><end>1582</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit79"><titleInfo><title>Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or = 65 years old.</title></titleInfo><name type="personal"><namePart type="given">W. A.</namePart><namePart type="family">Keitel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. J.</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H. M.</namePart><namePart type="family">El Sahly</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Gilbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Keitel, W. A., Treanor, J. J., El Sahly, H. M., Gilbert, A. et al., Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or = 65 years old. Vaccine 2009, 28, 379–385.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>379</start><end>385</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>379</start><end>385</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit80"><titleInfo><title>Global alert to avian influenza virus infection: From H5N1 to H7N9.</title></titleInfo><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Poovorawan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Pyungporn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Prachayangprecha</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Makkoch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Poovorawan, Y., Pyungporn, S., Prachayangprecha, S., Makkoch, J., Global alert to avian influenza virus infection: From H5N1 to H7N9. Pathog. Glob. Health 2013, 107, 217–223.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>217</start><end>223</end></extent></part><relatedItem type="host"><titleInfo><title>Pathog. Glob. Health</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>217</start><end>223</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit81"><titleInfo><title>Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957.</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Pappas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Viswanathan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Chandrasekaran</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Raman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pappas, C., Viswanathan, K., Chandrasekaran, A., Raman, R. et al., Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PLoS One 2010, 5, e11158.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>e11158</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>e11158</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit82"><titleInfo><title>Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil‐in‐water emulsion containing glucopyranosyl‐lipid A (SE+GLA) adjuvant.</title></titleInfo><name type="personal"><namePart type="given">J. J.</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Essink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Hull</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Treanor, J. J., Essink, B., Hull, S., Reed, S. et al., Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil‐in‐water emulsion containing glucopyranosyl‐lipid A (SE+GLA) adjuvant. Vaccine 2013, 31, 5760–5765.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>5760</start><end>5765</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>5760</start><end>5765</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit83"><titleInfo><title>Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.</title></titleInfo><name type="personal"><namePart type="given">N. A.</namePart><namePart type="family">Goji</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Nolan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Hill</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Wolff</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goji, N. A., Nolan, C., Hill, H., Wolff, M. et al., Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J. Infect. Dis. 2008, 198, 635–641.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>198</number></detail><extent unit="pages"><start>635</start><end>641</end></extent></part><relatedItem type="host"><titleInfo><title>J. Infect. Dis.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>198</number></detail><extent unit="pages"><start>635</start><end>641</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit84"><titleInfo><title>A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge.</title></titleInfo><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Tian</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu, G., Zhang, F., Shi, J., Tian, G. et al., A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge. Vaccine 2013, 31, 5398–5404.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>5398</start><end>5404</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>5398</start><end>5404</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit85"><titleInfo><title>H5N1 virus‐like particle vaccine elicits cross‐reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Khurana</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Verma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Verma</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Khurana, S., Wu, J., Verma, N., Verma, S. et al., H5N1 virus‐like particle vaccine elicits cross‐reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J. Virol. 2011, 85, 10945–10954.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>10945</start><end>10954</end></extent></part><relatedItem type="host"><titleInfo><title>J. Virol.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>10945</start><end>10954</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit86"><titleInfo><title>Safety and immunogenicity of a virus‐like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo‐controlled trial of adults in Mexico.</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Lopez‐Macias</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Ferat‐Osorio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Tenorio‐Calvo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Isibasi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lopez‐Macias, C., Ferat‐Osorio, E., Tenorio‐Calvo, A., Isibasi, A. et al., Safety and immunogenicity of a virus‐like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo‐controlled trial of adults in Mexico. Vaccine 2011, 29, 7826–7834.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>7826</start><end>7834</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>7826</start><end>7834</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit87"><titleInfo><title>Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross‐protection in vaccinated mice challenged with H7N9 virus.</title></titleInfo><name type="personal"><namePart type="given">G. E.</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. C.</namePart><namePart type="family">Flyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Raghunandan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith, G. E., Flyer, D. C., Raghunandan, R., Liu, Y. et al., Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross‐protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31, 4305–4313.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>4305</start><end>4313</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>4305</start><end>4313</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit88"><titleInfo><title>Influenza virus‐like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.</title></titleInfo><name type="personal"><namePart type="given">R. A.</namePart><namePart type="family">Bright</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. M.</namePart><namePart type="family">Carter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Daniluk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F. R.</namePart><namePart type="family">Toapanta</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bright, R. A., Carter, D. M., Daniluk, S., Toapanta, F. R. et al., Influenza virus‐like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25, 3871–3878.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3871</start><end>3878</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3871</start><end>3878</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit89"><titleInfo><title>Baculovirus‐expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use.</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Safdar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. M.</namePart><namePart type="family">Cox</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Safdar, A., Cox, M. M., Baculovirus‐expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin. Investig. Drugs 2007, 16, 927–934.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>927</start><end>934</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Opin. Investig. Drugs</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>927</start><end>934</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit90"><titleInfo><title>Influenza neuraminidase as a vaccine antigen.</title></titleInfo><name type="personal"><namePart type="given">M. C.</namePart><namePart type="family">Eichelberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Wan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eichelberger, M. C., Wan, H., Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol. 2015, 386, 275–299.</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>386</number></detail><extent unit="pages"><start>275</start><end>299</end></extent></part><relatedItem type="host"><titleInfo><title>Curr. Top. Microbiol. Immunol.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>386</number></detail><extent unit="pages"><start>275</start><end>299</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit91"><titleInfo><title>Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.</title></titleInfo><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Krammer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Palese</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Steel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krammer, F., Palese, P., Steel, J., Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 2015, 386, 301–321.</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>386</number></detail><extent unit="pages"><start>301</start><end>321</end></extent></part><relatedItem type="host"><titleInfo><title>Curr. Top. Microbiol. Immunol.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>386</number></detail><extent unit="pages"><start>301</start><end>321</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit92"><titleInfo><title>Development of the vault particle as a platform technology.</title></titleInfo><name type="personal"><namePart type="given">L. H.</namePart><namePart type="family">Rome</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V. A.</namePart><namePart type="family">Kickhoefer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rome, L. H., Kickhoefer, V. A., Development of the vault particle as a platform technology. ACS Nano 2013, 7, 889–902.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>889</start><end>902</end></extent></part><relatedItem type="host"><titleInfo><title>ACS Nano</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>889</start><end>902</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit93"><titleInfo><title>Al‐Tawfiq, J. A., Memish, Z. A., Middle East respiratory syndrome coronavirus: Transmission and phylogenetic evolution. Trends Microbiol. 2014.</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit94"><titleInfo><title>Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.</title></titleInfo><name type="personal"><namePart type="given">D. S.</namePart><namePart type="family">Hui</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z. A.</namePart><namePart type="family">Memish</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Zumla</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hui, D. S., Memish, Z. A., Zumla, A., Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr. Opin. Pulm. Med. 2014, 20, 233–241.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>233</start><end>241</end></extent></part><relatedItem type="host"><titleInfo><title>Curr. Opin. Pulm. Med.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>233</start><end>241</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit95"><titleInfo><title>Porcine epidemic diarrhoea virus: A comprehensive review of molecular epidemiology, diagnosis, and vaccines.</title></titleInfo><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Song</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Park</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Song, D., Park, B., Porcine epidemic diarrhoea virus: A comprehensive review of molecular epidemiology, diagnosis, and vaccines. Virus Genes 2012, 44, 167–175.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>167</start><end>175</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Genes</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>167</start><end>175</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit96"><titleInfo><title>The SARS‐CoV S glycoprotein.</title></titleInfo><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Xiao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. S.</namePart><namePart type="family">Dimitrov</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Xiao, X., Dimitrov, D. S., The SARS‐CoV S glycoprotein. Cell. Mol. Life Sci. 2004, 61, 2428–2430.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>2428</start><end>2430</end></extent></part><relatedItem type="host"><titleInfo><title>Cell. Mol. Life Sci.</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>2428</start><end>2430</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit97"><titleInfo><title>Current advancements and potential strategies in the development of MERS‐CoV vaccines.</title></titleInfo><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Jiang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Du</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhang, N., Jiang, S., Du, L., Current advancements and potential strategies in the development of MERS‐CoV vaccines. Expert Rev. Vaccines 2014, 13, 761–774.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>761</start><end>774</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev. Vaccines</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>761</start><end>774</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit98"><titleInfo><title>Drug targets for rational design against emerging coronaviruses.</title></titleInfo><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Zhao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Weber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhao, Q., Weber, E., Yang, H., Drug targets for rational design against emerging coronaviruses. Infect. Disord. Drug Targets 2013, 13, 116–127.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>116</start><end>127</end></extent></part><relatedItem type="host"><titleInfo><title>Infect. Disord. Drug Targets</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>116</start><end>127</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit99"><titleInfo><title>Baculovirus surface display of SARS coronavirus (SARS‐CoV) spike protein and immunogenicity of the displayed protein in mice models.</title></titleInfo><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Feng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Qu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Deng</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feng, Q., Liu, Y., Qu, X., Deng, H. et al., Baculovirus surface display of SARS coronavirus (SARS‐CoV) spike protein and immunogenicity of the displayed protein in mice models. DNA Cell Biol. 2006, 25, 668–673.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>668</start><end>673</end></extent></part><relatedItem type="host"><titleInfo><title>DNA Cell Biol.</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>668</start><end>673</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit100"><titleInfo><title>Antigenic and immunogenic characterization of recombinant baculovirus‐expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design.</title></titleInfo><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">He</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Heck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Lustigman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Jiang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">He, Y., Li, J., Heck, S., Lustigman, S., Jiang, S., Antigenic and immunogenic characterization of recombinant baculovirus‐expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design. J. Virol. 2006, 80, 5757–5767.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>5757</start><end>5767</end></extent></part><relatedItem type="host"><titleInfo><title>J. Virol.</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>5757</start><end>5767</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit101"><titleInfo><title>Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in mice.</title></titleInfo><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Lu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Bai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lu, X., Chen, Y., Bai, B., Hu, H. et al., Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in mice. Immunology 2007, 122, 496–502.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><extent unit="pages"><start>496</start><end>502</end></extent></part><relatedItem type="host"><titleInfo><title>Immunology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><extent unit="pages"><start>496</start><end>502</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit102"><titleInfo><title>Virus‐like particles of SARS‐like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells.</title></titleInfo><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Bai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bai, B., Hu, Q., Hu, H., Zhou, P. et al., Virus‐like particles of SARS‐like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One 2008, 3, e2685.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>e2685</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>e2685</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit103"><titleInfo><title>Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS‐like coronavirus generates humoral and cellular immune responses.</title></titleInfo><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Bai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Lu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Meng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Hu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bai, B., Lu, X., Meng, J., Hu, Q. et al., Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS‐like coronavirus generates humoral and cellular immune responses. Mol.Immunol. 2008, 45, 868–875.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>868</start><end>875</end></extent></part><relatedItem type="host"><titleInfo><title>Mol.Immunol.</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>868</start><end>875</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit104"><titleInfo><title>Effect of mucosal and systemic immunization with virus‐like particles of severe acute respiratory syndrome coronavirus in mice.</title></titleInfo><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Lu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lu, B., Huang, Y., Huang, L., Li, B. et al., Effect of mucosal and systemic immunization with virus‐like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 2010, 130, 254–261.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>130</number></detail><extent unit="pages"><start>254</start><end>261</end></extent></part><relatedItem type="host"><titleInfo><title>Immunology</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>130</number></detail><extent unit="pages"><start>254</start><end>261</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit105"><titleInfo><title>Chimeric severe acute respiratory syndrome coronavirus (SARS‐CoV) S glycoprotein and influenza matrix 1 efficiently form virus‐like particles (VLPs) that protect mice against challenge with SARS‐CoV.</title></titleInfo><name type="personal"><namePart type="given">Y. V.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. J.</namePart><namePart type="family">Massare</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. L.</namePart><namePart type="family">Barnard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Kort</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu, Y. V., Massare, M. J., Barnard, D. L., Kort, T. et al., Chimeric severe acute respiratory syndrome coronavirus (SARS‐CoV) S glycoprotein and influenza matrix 1 efficiently form virus‐like particles (VLPs) that protect mice against challenge with SARS‐CoV. Vaccine 2011, 29, 6606–6613.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>6606</start><end>6613</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>6606</start><end>6613</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit106"><titleInfo><title>Assembly and immunogenicity of coronavirus‐like particles carrying infectious bronchitis virus M and S proteins.</title></titleInfo><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Lv</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Yin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu, G., Lv, L., Yin, L., Li, X. et al., Assembly and immunogenicity of coronavirus‐like particles carrying infectious bronchitis virus M and S proteins. Vaccine 2013, 31, 5524–5530.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>5524</start><end>5530</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>5524</start><end>5530</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit107"><titleInfo><title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.</title></titleInfo><name type="personal"><namePart type="given">C. M.</namePart><namePart type="family">Coleman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y. V.</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Mu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. K.</namePart><namePart type="family">Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coleman, C. M., Liu, Y. V., Mu, H., Taylor, J. K. et al., Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014, 32, 3169–3174.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>3169</start><end>3174</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>3169</start><end>3174</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit108"><titleInfo><title>Chikungunya at the door – Deja vu all over again?</title></titleInfo><name type="personal"><namePart type="given">D. M.</namePart><namePart type="family">Morens</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. S.</namePart><namePart type="family">Fauci</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morens, D. M., Fauci, A. S., Chikungunya at the door – Deja vu all over again? N. Engl. J. Med. 2014, 371, 885–887.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>371</number></detail><extent unit="pages"><start>885</start><end>887</end></extent></part><relatedItem type="host"><titleInfo><title>N. Engl. J. Med.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>371</number></detail><extent unit="pages"><start>885</start><end>887</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit109"><titleInfo><title>Effective chikungunya virus‐like particle vaccine produced in insect cells.</title></titleInfo><name type="personal"><namePart type="given">S. W.</namePart><namePart type="family">Metz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Gardner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Geertsema</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T. T.</namePart><namePart type="family">Le</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Metz, S. W., Gardner, J., Geertsema, C., Le, T. T. et al., Effective chikungunya virus‐like particle vaccine produced in insect cells. PLoS Negl. Trop. Dis. 2013, 7, e2124.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>e2124</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS Negl. Trop. Dis.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>e2124</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit110"><titleInfo><title>Chikungunya virus‐like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.</title></titleInfo><name type="personal"><namePart type="given">S. W.</namePart><namePart type="family">Metz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B. E.</namePart><namePart type="family">Martina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">van den Doel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Geertsema</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Metz, S. W., Martina, B. E., van den Doel, P., Geertsema, C. et al., Chikungunya virus‐like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013, 31, 6092–6096.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>6092</start><end>6096</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>6092</start><end>6096</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit111"><titleInfo><title>Enhanced production of Chikungunya virus‐like particles using a high‐pH adapted Spodoptera frugiperda insect cell line.</title></titleInfo><name type="personal"><namePart type="given">J. M.</namePart><namePart type="family">Wagner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. D.</namePart><namePart type="family">Pajerowski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. L.</namePart><namePart type="family">Daniels</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. M.</namePart><namePart type="family">McHugh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wagner, J. M., Pajerowski, J. D., Daniels, C. L., McHugh, P. M. et al., Enhanced production of Chikungunya virus‐like particles using a high‐pH adapted Spodoptera frugiperda insect cell line. PLoS One 2014, 9, e94401.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e94401</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS One</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e94401</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit112"><titleInfo><title>Infectious Disease. Estimating the Ebola epidemic.</title></titleInfo><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Kupferschmidt</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kupferschmidt, K., Infectious Disease. Estimating the Ebola epidemic. Science 2014, 345, 1108.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>345</number></detail><extent unit="pages"><start>1108</start></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>345</number></detail><extent unit="pages"><start>1108</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit113"><titleInfo><title>Antibodies are necessary for rVSV/ZEBOV‐GP‐mediated protection against lethal Ebola virus challenge in nonhuman primates.</title></titleInfo><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Marzi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Engelmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Haberthur</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marzi, A., Engelmann, F., Feldmann, F., Haberthur, K. et al., Antibodies are necessary for rVSV/ZEBOV‐GP‐mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 1893–1898.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1893</start><end>1898</end></extent></part><relatedItem type="host"><titleInfo><title>Proc. Natl. Acad. Sci. U. S. A.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1893</start><end>1898</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit114"><titleInfo><title>Easy expression of the C‐terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi‐cistronic baculovirus system.</title></titleInfo><name type="personal"><namePart type="given">O. B.</namePart><namePart type="family">Villaflores</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. M.</namePart><namePart type="family">Hsei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Y.</namePart><namePart type="family">Teng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y. J.</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Villaflores, O. B., Hsei, C. M., Teng, C. Y., Chen, Y. J. et al., Easy expression of the C‐terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi‐cistronic baculovirus system. J. Virol. Methods 2013, 189, 58–64.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><extent unit="pages"><start>58</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>J. Virol. Methods</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><extent unit="pages"><start>58</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit115"><titleInfo><title>Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen‐presenting cells.</title></titleInfo><name type="personal"><namePart type="given">D. M.</namePart><namePart type="family">White</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Pellett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. A.</namePart><namePart type="family">Jensen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W. H.</namePart><namePart type="family">Tepp</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">White, D. M., Pellett, S., Jensen, M. A., Tepp, W. H. et al., Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen‐presenting cells. Infect. Immun. 2011, 79, 3388–3396.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>3388</start><end>3396</end></extent></part><relatedItem type="host"><titleInfo><title>Infect. Immun.</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>3388</start><end>3396</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit116"><titleInfo><title>Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Karczewski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Zorman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Miezeiewski</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Karczewski, J., Zorman, J., Wang, S., Miezeiewski, M. et al., Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine 2014, 32, 2812–2818.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2812</start><end>2818</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2812</start><end>2818</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit117"><titleInfo><title>Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin‐neutralising immune response.</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Maynard‐Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Ahern</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">McGlashan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Nugent</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maynard‐Smith, M., Ahern, H., McGlashan, J., Nugent, P. et al., Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin‐neutralising immune response. Vaccine 2014, 32, 700–705.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>700</start><end>705</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>700</start><end>705</end></extent></part></relatedItem></relatedItem><identifier type="istex">B294EB921F41F8D7654A04E9AC4BE437F004790D</identifier><identifier type="ark">ark:/67375/WNG-C4V1L7GV-1</identifier><identifier type="DOI">10.1002/biot.201400438</identifier><identifier type="ArticleID">BIOT201400438</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-C4V1L7GV-1/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000999 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000999 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B294EB921F41F8D7654A04E9AC4BE437F004790D
|texte= The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
}}
| This area was generated with Dilib version V0.6.33. |  |